

# Curriculum Vitae

# Personal information Sayeh Ahrabi

## Work experience

- - End date: present
    Position: Strategic director, medicinal products assessment
- Employer: Norwegian medicines agency/Norwegian medical products agency
  Start date: 012017

  - End date: 082025
- Position: Strategic director, Medicines supply chain and medical devices
  Byployer: Norwegian Medicines Agency
- - Start date: 012010 End date: 012017
  - Position: Head of section, quality assessment
- 4. Employer: Clavis PharmaStart date: 012004

  - End date: 122009 Position: Director Pharmaceutical R&D
  - Activities: Formulation development and manufacture for preclinical and clinical studies
  - Country: Norway
- 5. Employer: Weifa
  - Start date: 022003 End date: 122003
  - Position: Head of formulation development
  - $\begin{tabular}{ll} Activities: Formulation development \'(mainly tablets), upscaling and technical transfer to $$ (a) $ (b) $ (b) $ (c) $ (c)$
  - production facilities Country: Norway
- 6. Employer: Alpharma
  - Start date: 012001
  - End date: 012003
  - Position: Pharmaceutical advisor
  - Activities: Process development for tablets and semisolids, scale up and technical transfer from R&D to production facilities
- Country: Norway
  Employer: School of Pharmacy, University of Oslo
  - Start date: 082000 End date: 122000
  - Position: Senior lecturer
  - Activities: Develop a new practical course i pharmaceutical technology as well as planning the practical exam
  - Country: Norway

### Education and training

- Subject: University of Oslo, School of Pharmacy
  Start date: 011994

  - End date: 121999 Qualification: PhD (Dr.scient.)
  - Organisation: Pharmaceutical sciences and technology
  - Country: Norway
- 2. Subject: University of Oslo, School of Pharmacy
  - Start date: 081992 End date: 121993
  - Qualification: MScPharm
  - Organisation: Supplementary courses to the Pharmacy education that was started in Iran, and thesis within pharmaceutical sciences
- Country: Norway
  Subject: Centre for Entrepreneurship, University of Oslo
  - Start date: 082009
  - End date: 052012
  - Qualification: MSc Innovation and Entrepreneurship
  - Organisation: Innovation management and entrepreneurship Country: Norway

#### Additional information

#### **Publications**

Ahrabi SF, Heinämäki, J, Sande SA and Graffner, C. (2000). Influence of neutron activation factors on matrix tablets aimed for site specific delivery to colon. Eur. J. Pharm. Sci., 10, 225\_235. Ahrabi SF, Madsen G, Dyrstad K, Sande SA and Graffner C. (2000). Development of pectin matrix tablets for colonic delivery of model drug ropivacaine. Eur. J. Pharm. Sci., 10,  $43_{-}52$ . Ahrabi SF (1999). Radiolabelling of potential colonic delivery systems by neutron activation. An evaluation based on physicochemical properties of the excipients and formulations. Thesis for the

degree of Dr.Scient., University of Oslo. Ahrabi SF, Sande SA, Waaler T and Graffner C. (1999). Effects of thermal neutron irradiation on some potential excipients for colonic delivery systems. Drug Dev. Ind. Pharm., 25, 453\_462. Ahrabi SF, Sande SA, Waaler T and Graffner C. Influence of neutron activation factors on the physicochemical properties of suppositories and their excipients. Eur. J. Pharm. Sci., 8, 193\_201. Ahrabi SF. (1993). Stability of liposomes: oxidation of phospholipids and its relation to zeta potential variations. Thesis for the degree of Cand. Pharm., University of Oslo, Norway. Ahrabi SF, Hagen S, Myhren F. (2008). CP\_4126 oral product development: In\_silico absorption prediction, oral metabolic stability and preliminary bioavailability study in beagle dogs. Poster presentation at American Association of Pharmaceutical Scientists (AAPS) Annual Meeting, November 2008, Atlanta, GA, USA.

Projects

Memberships

Other Relevant Information

Page 2 of 2